Clinical trial · Observational
Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients
NCT07465458CI-TRIAL-00105664RASROP-003not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Carcinoma | Kidney Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiofrequency Ablation (RFA) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Technical success
- timeFrame
- up to 2 months post-procedure
- description
- ablation zone evaluated post-ablation
- measure
- Technical efficacy
- timeFrame
- up to 12 months
- description
- Abscence of tumor recurrence within the margin of the ablation zone or viable residual tumor on follow-up imaging
Secondary outcomes (12)
- measure
- Ablation related complications
- timeFrame
- up to 12 months
- description
- complications and adverse events
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Patient selection criteria will be those typically established by each participating center t with T1a primary renal tumors for which a Multidisciplinary Tumor Board has indicated as candidates for treatment with radiofrequency ablation.I Inclusion Criteria: * Age ≥18 years * Signed informed consent approved by the Ethics Committee prior to the ablation procedure. * RCC in stage T1a (size \<4 cm), single or multiple, histologically demonstrated by percutaneous biopsy before or within 30 days prior to ablation * Absence of comorbidities that contraindicate treatment * Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 at baseline screening. Exclusion Criteria: * No specific exclusion criteria are established for this clinical registry due to its observational nature. Each center will apply its own criteria according to its routine clinical practice.
References
Publications (0)
Data not yet available
No reference posted for this study.